PeptideDB

PD-L1-IN-3 2953044-29-4

PD-L1-IN-3 2953044-29-4

CAS No.: 2953044-29-4

PD-L1-IN-3 (Compound 4a) is a compound targeting PD-1/PD-L1. The IC50 for inhibiting PD-L1 is 4.97nM and the EC50 for Ju
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

PD-L1-IN-3 (Compound 4a) is a compound targeting PD-1/PD-L1. The IC50 for inhibiting PD-L1 is 4.97nM and the EC50 for Jurkat T cells is 2.70 μM. PD-L1-IN-3 can bind to PD-L1 dimers and prevent PD-1 from binding to PD-L1, thereby blocking PD-1 signaling. PD-L1-IN-3 could be used in research into diseases such as lung cancer and melanoma.

Physicochemical Properties


Molecular Formula C19H16CLFN2OS
Molecular Weight 374.86
CAS # 2953044-29-4
Appearance White to off-white solid powder
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro PD-L1-IN-3 (Compound 4a) (0.01-100 μM, 40 minutes) increases TCR-mediated activation of Jurkat cells while interfering with the binding of PD-1 and PD-L1 [1]. In PD-L1+ H358 tumors, PD-L1-IN-3 (0.01-100, 40 minutes) has a greater uptake, and its uptake is correlated with PD-L1 expression [1].
Cell Assay Cell Viability Assay[1]
Cell Types: Jurkat cells
Tested Concentrations: 0.01-100 μM
Incubation Duration: 40 min
Experimental Results: Observed EC50 value of 2.70 μM.

Immunofluorescence[1]
Cell Types: PD-L1+/−(H358 and ES2) tumor
Tested Concentrations: 0.01-100 μM
Incubation Duration: 40 min
Experimental Results: Observed 40-55% higher uptake in PD-L1+ H358 tumors than in wild-type counterparts. Failed to discriminate between wild-type and knock-out for ES2 slides.
Animal Protocol Animal/Disease Models: PD-L1+/− (H358 and ES2) tumor[1]
Doses: 0.01-100 μM
Route of Administration: incubation
Experimental Results: Observed 40-55% higher uptake in PD-L1+ H358 tumors than in wild-type counterparts. Failed to discriminate between wild-type and knock-out for ES2 slides.
References

[1]. Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors. J Med Chem. 2023 Jul 27;66(14):9577-9591.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.6677 mL 13.3383 mL 26.6766 mL
5 mM 0.5335 mL 2.6677 mL 5.3353 mL
10 mM 0.2668 mL 1.3338 mL 2.6677 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.